BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies, Inc. (BSGM) has announced a conference call on July 26, 2021, to discuss findings from its PURE EP 2.0 clinical trial, which involved 51 patients across three leading medical centers. The PURE EP™ System aims to enhance procedural efficiency in electrophysiology by improving signal fidelity for cardiac ablation procedures. More than 50 physicians have utilized the system in over 1000 patient cases. The trial's enrollments were completed in April 2021, and further presentations will take place at upcoming medical conventions.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced the completion of an underwritten public offering of 2,500,000 shares at $4.00 per share, raising gross proceeds of $10 million. The funds will support the commercialization of the PURE EP™ System, further research and development, and general corporate needs. Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for this offering, which follows a previously effective shelf registration statement. The prospectus relevant to the offering is available on the SEC's website.

BioSig Technologies has successfully installed its PURE EP(tm) system at New York Presbyterian, a leading healthcare institution in NYC, enhancing arrhythmia care. The FDA-cleared device aims to improve procedural efficiency in electrophysiology, supported by over 1,000 patient cases across various clinical sites. With cardiac arrhythmia affecting 33 million globally, the market for such innovations is significant. This launch is part of BioSig’s strategic rollout, targeting key areas in the Northeast for better patient outcomes.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced the pricing of a public offering of 2,500,000 shares of its common stock at $4.00 per share, expected to generate approximately $10 million in gross proceeds. If the underwriter exercises its option for an additional 15%, proceeds may reach $11.5 million. The offering is scheduled to close on July 7, 2021. Funds will support commercialization of the PURE EP™ System and ongoing R&D activities. Laidlaw & Company acts as the sole book-running manager.

BioSig Technologies (Nasdaq: BSGM) announced a public offering of its common stock, with the potential for an additional 15% of shares. The move aims to fund commercialization of the PURE EP™ System, support organizational growth, and continue research and development. The offering is contingent on market conditions, with no certainty regarding completion or terms. The relevant shelf registration statement was filed with the SEC and is effective as of January 12, 2021.

BioSig Technologies, Inc. (NASDAQ: BSGM) has surpassed its initial target of conducting 1000 patient cases with its PURE EP™ System, achieving this milestone at nine installation sites. The Company has raised its procedural volume goal to at least 1500 by the end of 2021, driven by increased technology adoption in electrophysiology. BioSig's expansion includes enhancing its commercial team and targeting key regions: the Northeast, Texas, and Florida. The ongoing rise in technology use signals a recovery from pandemic-related challenges, potentially positioning BioSig for strong performance in the latter half of 2021.

BioSig Technologies (Nasdaq: BSGM) will present its latest software for arrhythmia care at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27. The presentation will showcase advancements in the PURE EP(tm) System, designed to improve signal fidelity and procedural efficiency in electrophysiology. Since the targeted commercial launch in 2020, 55 physicians have conducted over 950 patient cases using the system, which has received FDA 510(k) clearance. Atrial fibrillation affects over 33 million globally, highlighting the software's potential impact in addressing this growing healthcare challenge.

BioSig Technologies (NASDAQ: BSGM) announced that data from its PURE EP(tm) System will be presented at the Heart Rhythm 2021 convention in Boston from July 28-31, 2021. Two significant presentations include "Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion" and "Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude During Radiofrequency Ablation." The PURE EP(tm) System has received FDA 510(k) clearance, with over 950 patient cases completed across multiple clinical sites. The company aims to enhance procedural efficiency in electrophysiology.

BioSig Technologies (Nasdaq: BSGM) announced its participation in the Heart Rhythm 2021 convention, scheduled for July 28-31, 2021, in Boston, MA. The company will showcase its PURE EP(tm) System, a cutting-edge signal processing platform designed for cardiac arrhythmia care. In April 2021, BioSig completed the enrollment of 51 patients for a clinical trial on various arrhythmia cases, including atrial fibrillation. The PURE EP(tm) System has received FDA 510(k) clearance and has been utilized in over 940 patient cases by 52 physicians across multiple sites.